Navigation Links
Orexigen Announces Successful Interim Analysis of Contrave Light Study
Date:11/25/2013

SAN DIEGO, Nov. 25, 2013 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced successful results of the interim analysis of the Light Study. Based on these results, the Company will resubmit the Contrave® New Drug Application (NDA) to the United States Food and Drug Administration (FDA) in the next few weeks with potential approval by June 2014. 

"The interim analysis of the Light Study clearly achieved the goal set by the FDA," said Michael Narachi, CEO of Orexigen.  "The resubmission will contain an unprecedented amount of cardiovascular outcomes data for an obesity therapeutic, and we are confident these data will support a favorable benefit:risk assessment for Contrave."

The FDA previously agreed that if the interim analysis meets the specified criteria to exclude cardiovascular risk, Contrave could be approved. The pre-specified criteria for the interim analysis is to exclude a hazard ratio of 2.0, using the upper bound of the 95% confidence interval, for excess risk of major adverse cardiovascular events (MACE) in patients receiving Contrave as compared to placebo. In addition to meeting the pre-specified criteria for excluding cardiovascular risk, no new safety signals were observed.

"Takeda is excited about this major milestone for Contrave," said Doug Cole, President of Takeda Pharmaceuticals U.S.A., Inc., Orexigen's partner for Contrave in North America. "Takeda is pleased to partner with Orexigen to develop a therapeutic option that has the potential to help patients achieve meaningful and sustained weight loss over time."

Conference Call This Morning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) The Orexigen management team will host a teleconference and webcast to d
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015   Gulf Coast Tattoo Removal is ... the cutting-edge Astanza Duality laser in Southern Mississippi ... their tattoo regret and take back control of their skin. The ... extends its services to Biloxi , ... "With tattoo regret being as prevalent as it is, I was ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6mlrvg/an_introduction ) ... Introduction to Medical Device Software: Regulations and Requirements ... to their offering. This course ... and requirements that apply to Medical Device Software. ... life examples and state-of- the-art practices identified from ...
(Date:9/2/2015)... , Sept. 2, 2015  Research and ... of the "An Introduction to the Medical ... conference to their offering. ... European medical device legislation. It will explain the ... of Notified Bodies, how to choose one and ...
Breaking Medicine Technology:Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... TRIANGLE PARK, N.C., Oct. 17 CeNeRx BioPharma,Inc., ... for diseases of the central nervous system, today ... trial for its lead product candidate,Tyrima(TM) for the ... selective and reversible member of a novel class ...
... Berlin Heart Inc. today announced,its EXCOR(R) Pediatric ventricular assist ... clinical trial in the United,States of America. The U.S ... Plan for the IDE study of the device., ... the prospective,IDE study to begin initially at 10 centres ...
Cached Medicine Technology:CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 2CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 3Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 2Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 3
(Date:9/2/2015)... ... September 02, 2015 , ... ... large stream of mixed documents that include EOBs, payments, and payment related documents. ... the data needed to reconcile their billing, with one efficient process and interface,“ ...
(Date:9/2/2015)... Pittsburgh, PA (PRWEB) , ... September 02, 2015 ... ... the Health Sciences clinical and academic partnership has earned international recognition as a ... rare genetic disorder that can cause sudden, catastrophic internal bleeding and stroke. ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... largest and fastest-growing interim clinical staffing companies, has completed a recapitalization with ... , BPOC and Heritage Group each offer extensive expertise and ...
(Date:9/2/2015)... Kansas City, KS (PRWEB) , ... September 02, 2015 , ... ... recently opened its newest office in Kansas – its Johnson County location. ... backgrounds in healthcare. Mike has a registered nurse background and spent over 20 years ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to be ... risk of getting ovarian cancer in her lifetime is approximately 1 in 75. This ... ovarian cancer, and 14,000 will die. , There is no test to detect ...
Breaking Medicine News(10 mins):Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3
... , , WASHINGTON, July 24 ... today in support of the minimum wage increase from $6.55 an hour ... minimum wage increase is an important step in recovering our economy, rebuilding ... it is only one of three prongs necessary to create a real ...
... common, but labeling is not required, report states , ... "enhance" uncooked meat and poultry can pose serious health ... Many fresh meat and poultry products are injected with ... not required to be listed on food labels, according ...
... , , CLEVELAND, July 24 /PRNewswire/ ... access for the uninsured and underinsured to a wide range of health ... 25 and 26, at the W.O. Walker Center, 10524 Euclid Ave. The ... provide 1100 medical, 300 vision and 200 dental patient visits. Appointments ...
... , CHICAGO, July 24 ... in designing and manufacturing portable rechargeable systems, today ... single-output power supplies. The new 350-watt series, designed ... delivers an industry-leading converter efficiency of up to ...
... WESTBROOK, Maine, July 24 IDEXX Laboratories, Inc. (Nasdaq: ... second quarter of 2009 were $265.7 million compared to $280.6 ... as defined below, was 5%. Earnings per diluted share ("EPS") ... to $0.63 for the same period in the prior year. ...
... ... Texans find affordable, direct access to medical lab testing through Any Lab Test Now®. , ... Plano, TX (PRWEB) July 24, 2009 -- This ... company has found its niche. Opened December 2008, Any Lab Test Now® in ...
Cached Medicine News:Health News:Fresh-Meat Additives May Be Dangerous for Kidney Patients 2Health News:U.S. Senator Sherrod Brown to Lend Support at MedWorks' Free Medical Clinic This Weekend 2Health News:Convection Cooled 350-Watt Open Frame Power Supply Meets Medical and Industrial Safety Standards 2Health News:IDEXX Laboratories Announces Second Quarter Results 2Health News:IDEXX Laboratories Announces Second Quarter Results 3Health News:IDEXX Laboratories Announces Second Quarter Results 4Health News:IDEXX Laboratories Announces Second Quarter Results 5Health News:IDEXX Laboratories Announces Second Quarter Results 6Health News:IDEXX Laboratories Announces Second Quarter Results 7Health News:IDEXX Laboratories Announces Second Quarter Results 8Health News:IDEXX Laboratories Announces Second Quarter Results 9Health News:IDEXX Laboratories Announces Second Quarter Results 10Health News:IDEXX Laboratories Announces Second Quarter Results 11Health News:IDEXX Laboratories Announces Second Quarter Results 12Health News:IDEXX Laboratories Announces Second Quarter Results 13Health News:IDEXX Laboratories Announces Second Quarter Results 14Health News:IDEXX Laboratories Announces Second Quarter Results 15Health News:IDEXX Laboratories Announces Second Quarter Results 16Health News:IDEXX Laboratories Announces Second Quarter Results 17Health News:IDEXX Laboratories Announces Second Quarter Results 18Health News:IDEXX Laboratories Announces Second Quarter Results 19Health News:IDEXX Laboratories Announces Second Quarter Results 20Health News:IDEXX Laboratories Announces Second Quarter Results 21Health News:IDEXX Laboratories Announces Second Quarter Results 22Health News:Cost-Conscious Texans Find Relief with Direct Access Lab Testing 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: